Correction: Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer

Shiqi Li; Yi Zhu; Zhen Liang; Xiao Wang; Shuai Meng; Xin Xu; Xianglai Xu; Jian Wu; Alin Ji; Zhenghui Hu; Yiwei Lin; Hong Chen; Yeqing Mao; Wei Wang; Xiangyi Zheng; Ben Liu; Liping Xie

doi:10.18632/oncotarget.26624

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer

PDF | How to cite

Oncotarget. 2019; 10:684-684. https://doi.org/10.18632/oncotarget.26624

Metrics: PDF 1560 views | ?

Shiqi Li^1,*, Yi Zhu^1,*, Zhen Liang¹, Xiao Wang¹, Shuai Meng¹, Xin Xu¹, Xianglai Xu¹, Jian Wu¹, Alin Ji¹, Zhenghui Hu¹, Yiwei Lin¹, Hong Chen¹, Yeqing Mao¹, Wei Wang¹, Xiangyi Zheng¹, Ben Liu¹ and Liping Xie¹

¹ Department of Urology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310003, Zhejiang, PR China
^* These authors contributed equally to this work and are Co-first authors

Published: January 18, 2019

This article has been corrected: The correct Grant number information is given below:

ACKNOWLEDGMENTS AND FUNDING

This work was supported by the Public Welfare Technology Application Research project of Zhejiang Provincial Science, Technology Department of China (Grant No. 2014C33198), Zhejiang Provincial Natural Science Foundation of China (Grant No. LY16H160015), National Natural Science Foundation of China (Grant No.81372773, 81472375, 81402096, 81502215), scientific research foundation of the ministry of public health (WKJ2012-2-009), Zhejiang province key project of science and technology (2014C04008-2).

Original article: Oncotarget. 2016; 7:51773-51783. DOI: https://doi.org/10.18632/oncotarget.10575.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26624

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer